Proteologics Ltd is a biopharmaceutical company exploiting the ubiquitin system for the discovery and development of novel therapeuticsforcancer treatment.
The reserach was performed byidentifying correlations between ubiquitin pathway components and pathological conditions.
The ubiquitin system was discovered by two Israeli Nobel Prize Laureates, Avram Hershko and Aaron Ciechanover.
Proteologics hasexploited the ubiquitin system for the novel therapeutics,focusing primarily on discovering inhibitors for specific E3 ubiquitin ligases.
In 2012, XTLBiopharmaceuticals Ltd. (Pink Sheets:XTLBY; TASE:XTL) acquired 31% stake in Proteologics. Until then,Teva Pharmaceutical Industries Ltd. was the controlling shareholder in Proteologics.
In Sept. 2013, Zmiha Investment House Ltd. (TASE: TZMI) has acquired control of Proteologics Ltd. from XTL Biopharmaceuticals Ltd. for NIS 12.1 million, including the control premium.
Zmiha, a licensee in the Yam 3 offshore oil and gas exploration license, bought 6,738,828 Proteologics shares, 44.95% of the company.
At that point, Proteologicsdecided to freeze its research activity. However, itsStocks have been tradedontheTASE.
In addition, Proteologicshas several initial joint-development agreements with big pharma companies.